Skip to content

Posts by Keyan Salari, MD, PhD

  • In a multicenter case–control study, Massachusetts General Hospital researchers validated a new urinary comprehensive genomic profiling test, which requires only a urine specimen, for detecting urothelial carcinoma in patients with hematuria and predicting recurrence before clinical signs or symptoms appear.

  • The Prostate Cancer Genetics Program at Massachusetts General Hospital explores whether MRI prostate cancer screening detects disease earlier than standard tests in men with genetic mutations linked to prostate cancer.

  • While classic serum tumor markers like α-fetoprotein and b-HCG are the gold standard for managing testicular germ cell tumors, microRNA are emerging as promising biomarkers with superior performance. Circulating tumor DNA and circulating tumor cells may prove to be important with further study.

  • In this video, Keyan Salari, MD, PhD, discusses his team's work to identify the features of seemingly indolent prostate cancers that actually make them more aggressive.

  • Keyan Salari, MD, PhD, director of the High-risk Prostate Cancer Clinic in the Department of Urology at Massachusetts General Hospital, and a urologic oncologist with the Mass General Cancer Center, discusses the innovative work he and his team are doing to advance prostate cancer patient care.

  • The Prostate Cancer High-Risk Clinic from the Massachusetts General Hospital Department of Urology and the Mass General Cancer Center, offers advanced genetic testing and cancer screening, and expands insights on the genetics of prostate cancer.

  • According to a recent study, 5-alpha reductase inhibitors (5-ARIs) do not lower the risk of development or reoccurrence of bladder cancer. Future research is needed to identify an alternate strategy for chemoprevention of bladder cancer.

  • A large, two-institution retrospective study with prolonged follow-up showed that active surveillance is safe and effective for properly selected men younger than 60 years of age who have low-risk prostate cancer.


Keyan Salari, MD, PhD, is a urologic oncologist at the Massachusetts General Hospital and Harvard Medical School. He is a urologic surgeon specialized in the treatment of genitourinary cancers using open, laparoscopic, and robotic surgery techniques. His research focuses on applying cancer genomics and computational biology methods to advance precision cancer medicine for genitourinary malignancies. 

Dr. Salari is a faculty member of the Department of Urology and a Urologic Oncologist at the Mass General Cancer Center. He graduated with honors from the University of California at Berkeley with a B.A. in molecular and cellular biology, where he was awarded the Spencer W. Brown Award and was a Howard Hughes Medical Institute Biology Fellow. He earned his MD and PhD in Genetics from Stanford University School of Medicine in the NIH Medical Scientist Training Program. He trained in General Surgery and Urology at the Massachusetts General Hospital and subsequently completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Salari’s clinical practice focuses on the surgical treatment of urologic cancers with a particular emphasis on prostate cancer and testicular cancer. He serves as Director of the Prostate Cancer Genetics Program, where families that may have a hereditary predisposition to prostate cancer are offered genetic testing, cancer screening, and support. His research interests focus on leveraging a variety of genomic technologies and computational biology methods to gain insight into the pathobiology of prostate cancer, with the goal of improving early detection of clinically significant prostate cancer and distinguishing indolent from aggressive disease to guide treatment decisions.

Urology Care at Mass General

The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.